CN116549612A - Antibacterial composition containing plant stem cell factor and preparation method thereof - Google Patents
Antibacterial composition containing plant stem cell factor and preparation method thereof Download PDFInfo
- Publication number
- CN116549612A CN116549612A CN202310535092.2A CN202310535092A CN116549612A CN 116549612 A CN116549612 A CN 116549612A CN 202310535092 A CN202310535092 A CN 202310535092A CN 116549612 A CN116549612 A CN 116549612A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- plant stem
- cell factor
- extract
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 241000196324 Embryophyta Species 0.000 title claims abstract description 37
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000000419 plant extract Substances 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 9
- 241000894006 Bacteria Species 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims description 54
- 238000001556 precipitation Methods 0.000 claims description 25
- 230000003385 bacteriostatic effect Effects 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 15
- 239000003242 anti bacterial agent Substances 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 241000628997 Flos Species 0.000 claims description 12
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 12
- 229940093265 berberine Drugs 0.000 claims description 12
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 230000000975 bioactive effect Effects 0.000 claims description 11
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 claims description 11
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 claims description 11
- 229930182470 glycoside Natural products 0.000 claims description 10
- 150000002338 glycosides Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 241000405414 Rehmannia Species 0.000 claims description 9
- 238000004821 distillation Methods 0.000 claims description 9
- 241001570521 Lonicera periclymenum Species 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 8
- 239000004599 antimicrobial Substances 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 claims description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 230000004071 biological effect Effects 0.000 claims description 6
- 239000013522 chelant Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 235000008434 ginseng Nutrition 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 230000000840 anti-viral effect Effects 0.000 claims description 5
- 239000004909 Moisturizer Substances 0.000 claims description 4
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 230000001333 moisturizer Effects 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims description 3
- 206010061459 Gastrointestinal ulcer Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 244000173853 Sanguisorba officinalis Species 0.000 claims description 3
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 230000003467 diminishing effect Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 229940089161 ginsenoside Drugs 0.000 claims description 3
- 229930182494 ginsenoside Natural products 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 244000000074 intestinal pathogen Species 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000003892 spreading Methods 0.000 claims description 3
- 230000007480 spreading Effects 0.000 claims description 3
- 229940032094 squalane Drugs 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 244000131316 Panax pseudoginseng Species 0.000 claims 17
- 235000007516 Chrysanthemum Nutrition 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- 244000133098 Echinacea angustifolia Species 0.000 claims 1
- 244000303040 Glycyrrhiza glabra Species 0.000 claims 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims 1
- 241000245240 Lonicera Species 0.000 claims 1
- 240000000249 Morus alba Species 0.000 claims 1
- 235000008708 Morus alba Nutrition 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 240000002948 Ophiopogon intermedius Species 0.000 claims 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims 1
- 235000006751 Platycodon Nutrition 0.000 claims 1
- 244000274050 Platycodon grandiflorum Species 0.000 claims 1
- 244000197580 Poria cocos Species 0.000 claims 1
- 235000008599 Poria cocos Nutrition 0.000 claims 1
- 235000014134 echinacea Nutrition 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims 1
- 235000011477 liquorice Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims 1
- 229930189914 platycodon Natural products 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 abstract description 3
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 241000208340 Araliaceae Species 0.000 description 37
- 239000002075 main ingredient Substances 0.000 description 6
- 244000167230 Lonicera japonica Species 0.000 description 4
- 235000017617 Lonicera japonica Nutrition 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 2
- 241000050051 Chelone glabra Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 241000219784 Sophora Species 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940088623 biologically active substance Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 206010061126 Escherichia infection Diseases 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 208000020612 escherichia coli infection Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of preparation of antibacterial compositions containing plant stem cell factors, and discloses an antibacterial composition containing plant stem cell factors and a preparation method thereof. The composition can be used for sterilizing and inhibiting the growth of various bacteria, has various effects of moisturizing, repairing, resisting oxidation and the like, and can treat various bacterial infections, and the composition has better biocompatibility and safety because the composition is prepared from natural plant extracts/derivatives.
Description
Technical Field
The invention belongs to the technical field of preparation of antibacterial compositions containing plant stem cell factors, and particularly relates to an antibacterial composition containing plant stem cell factors and a preparation method thereof.
Background
The stem cell factor is a signal protein which can stimulate cell proliferation and differentiation, has the function of promoting cell regeneration and repair, has wide application prospect in the medical and cosmetic fields, is a common and serious problem in the medical and sanitary fields, is widely applied to the medical and sanitary fields, has strong drug resistance aiming at partial bacteria although a plurality of antibiotics are used for treating the bacterial infection, and gradually weakens the antibacterial effect of the antibiotics, and meanwhile, the traditional antibiotic treatment has strong pertinence, can cause the drug resistance and other side effects of the antibiotics, has poor treatment and moisturizing effects, so that a natural antibacterial agent which has a broad-spectrum antibacterial effect and can simultaneously achieve various repairing and moisturizing effects has important clinical application value, and therefore, the antibacterial composition containing the plant stem cell factor and the preparation method thereof are provided.
Disclosure of Invention
The invention aims to provide a bacteriostatic composition containing plant stem cell factors and a preparation method thereof, which are used for solving the problems in the background technology.
In order to achieve the above object, the present invention provides the following technical solutions:
a bacteriostatic composition containing plant stem cell factors, which comprises the following components:
(1) Ginseng plant stem cell factor;
(2) One or more antimicrobial agents;
(3) Positively charged plant extracts/derivatives;
(4) A natural humectant;
(5) A biologically active substance;
(6) One or more auxiliary materials.
Preferably, the ginseng plant stem cell factor is ginsenoside, and the ginseng plant stem cell factor obtained by extracting, purifying and drying ginseng has antibacterial, antiviral and antitumor biological activities.
Preferably, the antibacterial agent may be selected from one or more of berberine, dencichine, lonicera japonica extract, pachyman, rehmanniae radix Preparata glycoside, cortex Mori extract, and Echinacoside,
(1) Berberine is extracted from Coptidis rhizoma as main ingredient;
(2) Dencichine is a main component extracted from Notoginseng radix:
(3) The honeysuckle extract is extracted from flos Lonicerae;
(4) Pachyman is the main ingredient extracted from Poria;
(5) The prepared rehmannia root glycoside is extracted from the main component of prepared rehmannia root;
(6) The cortex Mori extract is prepared from cortex Mori:
(7) Echinacoside is the main ingredient extracted from Echinacoside,
the berberine, the sanchinin, the honeysuckle extract, the pachyman, the prepared rehmannia root glycoside, the sanguisorba officinalis extract and the echinacoside have broad-spectrum antibacterial, antiviral and antitumor biological activities, and the berberine and the honeysuckle extract also have good inhibition effects on intestinal pathogens and respiratory pathogens.
Preferably, the natural humectant is one or more of hyaluronic acid, glycerol, natural plant essence, squalane and the like, and the bioactive substances are one or more of vitamin E, collagen, honey and the like.
Preferably, the auxiliary material is one or more substances selected from the following compositions:
(1) The buffer comprises the components of the baical skullcap root extract, the lightyellow sophora root extract and the white paeony root extract, has the functions of clearing heat and detoxicating, diminishing inflammation and easing pain, resisting bacteria and resisting viruses, and can effectively relieve symptoms such as gastrointestinal inflammation, ulcer and the like;
(2) The auxiliary agent comprises polymer and solvent;
(3) Other auxiliary materials include antioxidants and preservatives.
Preferably, the plant extract/derivative comprises extract/derivative of one or more plants selected from radix Ophiopogonis, glycyrrhrizae radix, radix Platycodi, folium Mori, flos Chrysanthemi, mume fructus and flos Lonicerae, and the positive charge of the plant extract/derivative is achieved by: the plant extracts/derivatives are subjected to a plasma chemical reaction in a plasma reactor and then spread on a negatively charged wafer substrate to attract positive charges to chelate with the plant extracts/derivatives and to wick away negative charges through the positively charged wafer substrate disposed in the opposite direction.
The preparation method of the antibacterial composition containing the plant stem cell factor comprises the following steps:
s1: firstly, ginseng is taken, water is added, distillation and extraction are carried out under the conditions of the temperature of 65 ℃ to 75 ℃ and the vacuum degree of 0.06Mpa to 0.07Mpa, when the volume of distillate is half of the water adding amount, distillation is stopped, and collection is carried out, and at the moment, a first distillate can be obtained;
s2: continuously adding water into the rest feed liquid, then distilling and extracting at 70-80 ℃ and 0.05-0.06 Mpa, stopping distillation when the volume of the distillate is half of the water adding amount, and collecting, wherein a second distillate can be obtained;
s3: mixing the first distillate and the second distillate obtained in the step S1, and obtaining an extract containing the ginseng plant stem cell factor;
s4: the extract containing the ginseng plant stem cell factor is purified by adopting an ethanol fractional precipitation method, and the precipitation amounts are respectively 1.68%, 1.37%, 3.47%, 41.70%, 15.26%, 7.25%, 4.71% and 3.13%, the precipitation I is detected to the precipitation 8 by HPLC, and the detection result shows that the proportion of the main peak of the precipitation component is gradually increased along with the increase of the ethanol addition amount, and the proportion of the main peak of the precipitation component is increased from 72.3% of the precipitation 1 to 96.6% of the precipitation 8. The purity of the sediment 5 to the sediment 8 is above 96 percent, and the molecular mass is about 1800D, which can be regarded as the same substance, and then the substances are combined, and the purified substance containing the ginseng plant stem cell factor can be obtained at the moment;
s5: mixing the purified ginseng plant stem cell factor-containing material with one or more antimicrobial agents, and then obtaining a primary ginseng plant stem cell factor-containing mixture;
s6: preparing extracts/derivatives of one or more plants selected from radix Ophiopogonis, glycyrrhrizae radix, radix Platycodi, folium Mori, flos Chrysanthemi, mume fructus and flos Lonicerae, treating the extracts/derivatives in a plasma reactor for 0-24 hr for plasma chemical reaction, spreading on negatively charged wafer substrate to attract positive charges to chelate with the extracts/derivatives, sucking negative charges away via positively charged wafer substrate arranged in opposite direction to obtain positively charged extracts/derivatives, and mixing the positively charged extracts/derivatives with primary mixture containing Ginseng plant stem cell factor to obtain secondary mixture containing Ginseng plant stem cell factor;
s7: mixing the secondary mixture containing the ginseng plant stem cell factor with one or more natural moisturizers and bioactive substances, and then obtaining a tertiary mixture containing the ginseng plant stem cell factor;
s8: adding one or more auxiliary materials into the tertiary mixture containing the ginseng plant stem cell factor, and mixing to prepare the antibacterial composition containing the ginseng plant stem cell factor.
Preferably, in the preparation method S5, S6 and S8 steps of the bacteriostatic composition: the total mass percentage of the antibacterial agent is 0.1 to 10 percent; the concentration of the positively charged plant extract/derivative ranges from 0.0001mg/ml to 100mg/ml, and the total mass percentage of the auxiliary material is 90% to 99.9%.
Preferably, the ratio of the antibacterial agent, the natural humectant and the bioactive substances mixed in the steps S5 and S7 of the preparation method of the antibacterial composition is 3:1:1.
Preferably, the antibacterial composition containing plant stem cell factor in the preparation method S8 can be prepared into oral medicines of 0.1 to 10 g, external medicines of 0.5 to 5 g and injections of 0.05 to 1 g.
The beneficial effects of the invention are as follows:
1. the invention obtains a purified product containing the purified ginseng plant stem cell factor by extracting the ginseng plant stem cell factor and then purifying the extract, then mixes the purified ginseng plant stem cell factor with one or more antibacterial agents to obtain a primary mixture, then mixes the primary mixture with positively charged plant extracts/derivatives to obtain a secondary mixture, then mixes the secondary mixture with one or more natural moisturizing agents and bioactive substances to obtain a tertiary mixture containing the ginseng plant stem cell factor, finally adds one or more auxiliary materials into the tertiary mixture, thereby preparing a bacteriostatic composition containing the ginseng plant stem cell factor, wherein the positively charged plant extracts/derivatives can enable the bacteriostatic composition to contain stable positive charges, and the positive charges in the bacteriostatic composition can absorb viruses when in use due to the negatively charged areas on the surfaces of the viruses, so that the viral envelopes can be broken down and the viral structures can be destroyed, and the antibacterial agents in the bacteriostatic composition are combined, so that the effects of killing and inhibiting the growth of various bacteria can be achieved, meanwhile, the bacteriostatic composition has the effects of moisturizing, repairing and antioxidation effects and the like can be used for treating various infections, and the natural and/or the like can be prepared with the natural and safe and compatible bacteriostasis composition.
Drawings
FIG. 1 is a bar graph of the fractional precipitation of a plant stem cell extract of the present invention.
Description of the embodiments
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Examples
The embodiment of the invention provides a bacteriostatic composition containing plant stem cell factors, which comprises the following components:
(1) Ginseng plant stem cell factor;
(2) One or more antimicrobial agents;
(3) Positively charged plant extracts/derivatives;
(4) A natural humectant;
(5) A biologically active substance;
(6) One or more auxiliary materials.
In one embodiment, the ginseng plant stem cell factor is ginsenoside, and the ginseng plant stem cell factor obtained by extracting, purifying and drying ginseng has antibacterial, antiviral and antitumor biological activities.
In one embodiment, the antimicrobial agent may be selected from one or more of berberine, dencichine, lonicera japonica essence, pachyman, rehmanniae radix Preparata glycoside, kaempferide, and Echinacoside,
(1) Berberine is extracted from Coptidis rhizoma as main ingredient;
(2) Dencichine is a main component extracted from Notoginseng radix:
(3) The honeysuckle extract is extracted from flos Lonicerae;
(4) Pachyman is the main ingredient extracted from Poria;
(5) The prepared rehmannia root glycoside is extracted from the main component of prepared rehmannia root;
(6) The cortex Mori extract is prepared from cortex Mori:
(7) Echinacoside is the main ingredient extracted from Echinacoside,
berberine, sanchinin, lonicera japonica extract, pachyman, prepared rehmannia root glycoside, sanguisorba officinalis extract and echinacoside have broad-spectrum antibacterial, antiviral and antitumor biological activities, and berberine and lonicera japonica extract also have good inhibition effects on intestinal pathogens and respiratory pathogens.
In one embodiment, the natural humectant is one or more of hyaluronic acid, glycerol, natural plant essence, squalane, etc., and the bioactive substance is one or more of vitamin E, collagen, mel, etc.
In one embodiment, the auxiliary material is one or more substances selected from the following compositions:
(1) The buffer comprises the components of the baical skullcap root extract, the lightyellow sophora root extract and the white paeony root extract, has the functions of clearing heat and detoxicating, diminishing inflammation and easing pain, resisting bacteria and resisting viruses, and can effectively relieve symptoms such as gastrointestinal inflammation, ulcer and the like;
(2) The auxiliary agent comprises polymer and solvent;
(3) Other auxiliary materials include antioxidants and preservatives.
In one embodiment, the plant extract/derivative comprises extract/derivative of one or more plants selected from radix Ophiopogonis, glycyrrhrizae radix, radix Platycodi, folium Mori, flos Chrysanthemi, mume fructus, and flos Lonicerae, and the positive charge of the plant extract/derivative is achieved by: the plant extracts/derivatives are subjected to a plasma chemical reaction in a plasma reactor and then spread on a negatively charged wafer substrate to attract positive charges to chelate with the plant extracts/derivatives and to wick away negative charges through the positively charged wafer substrate disposed in the opposite direction.
Example 2: the preparation method of the antibacterial composition containing the plant stem cell factor comprises the following steps:
s1: firstly, ginseng is taken, water is added, distillation and extraction are carried out under the conditions of the temperature of 65 ℃ to 75 ℃ and the vacuum degree of 0.06Mpa to 0.07Mpa, when the volume of distillate is half of the water adding amount, distillation is stopped, and collection is carried out, and at the moment, a first distillate can be obtained;
s2: continuously adding water into the rest feed liquid, then distilling and extracting at 70-80 ℃ and 0.05-0.06 Mpa, stopping distillation when the volume of the distillate is half of the water adding amount, and collecting, wherein a second distillate can be obtained;
s3: mixing the first distillate and the second distillate obtained in the step S1, and obtaining an extract containing the ginseng plant stem cell factor;
s4: the extract containing the ginseng plant stem cell factor is purified by adopting an ethanol fractional precipitation method, and the precipitation amounts are respectively 1.68%, 1.37%, 3.47%, 41.70%, 15.26%, 7.25%, 4.71% and 3.13%, the precipitation I is detected to the precipitation 8 by HPLC, and the detection result shows that the proportion of the main peak of the precipitation component is gradually increased along with the increase of the ethanol addition amount, and the proportion of the main peak of the precipitation component is increased from 72.3% of the precipitation 1 to 96.6% of the precipitation 8. The purity of the sediment 5 to the sediment 8 is above 96 percent, and the molecular mass is about 1800D, which can be regarded as the same substance, and then the substances are combined, and the purified substance containing the ginseng plant stem cell factor can be obtained at the moment;
s5: mixing the purified ginseng plant stem cell factor-containing material with one or more antimicrobial agents, and then obtaining a primary ginseng plant stem cell factor-containing mixture;
s6: preparing extracts/derivatives of one or more plants selected from radix Ophiopogonis, glycyrrhrizae radix, radix Platycodi, folium Mori, flos Chrysanthemi, mume fructus and flos Lonicerae, treating the extracts/derivatives in a plasma reactor for 0-24 hr for plasma chemical reaction, spreading on negatively charged wafer substrate to attract positive charges to chelate with the extracts/derivatives, sucking negative charges away via positively charged wafer substrate arranged in opposite direction to obtain positively charged extracts/derivatives, and mixing the positively charged extracts/derivatives with primary mixture containing Ginseng plant stem cell factor to obtain secondary mixture containing Ginseng plant stem cell factor;
s7: mixing the secondary mixture containing the ginseng plant stem cell factor with one or more natural moisturizers and bioactive substances, and then obtaining a tertiary mixture containing the ginseng plant stem cell factor;
s8: adding one or more auxiliary materials into the tertiary mixture containing the ginseng plant stem cell factor, and mixing to prepare the antibacterial composition containing the ginseng plant stem cell factor.
In one embodiment, the preparation method of the bacteriostatic composition comprises the steps of S5, S6 and S8: the total mass percentage of the antibacterial agent is 0.1 to 10 percent; the concentration of the positively charged plant extract/derivative ranges from 0.0001mg/ml to 100mg/ml, and the total mass percentage of the auxiliary material is 90% to 99.9%.
In one embodiment, the ratio of the antimicrobial agent, the natural humectant and the bioactive substances mixed in steps S5 and S7 of the preparation method of the bacteriostatic composition is 3:1:1.
In one embodiment, the antibacterial composition containing plant stem cell factor in the preparation method S8 of the antibacterial composition can be prepared into oral medicines of 0.1 to 10 g, external medicines of 0.5 to 5 g and injections of 0.05 to 1 g.
In one embodiment, the bacteriostatic composition comprising plant stem cell factor in step S8 of the preparation method of the bacteriostatic composition can be used for treating various bacterial infections including, but not limited to, pneumococcal infection, escherichia coli infection, staphylococcus aureus infection, streptococcus infection.
It is noted that relational terms such as first and second, and the like are used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Moreover, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (10)
1. A bacteriostatic composition containing plant stem cell factor, which is characterized in that: the plant stem cell factor-containing antibacterial composition comprises ginseng plant stem cell factor, one or more antibacterial agents, positively charged plant extracts/derivatives, natural moisturizers, bioactive substances and one or more auxiliary materials.
2. A bacteriostatic composition according to claim 1, comprising plant stem cell factor, characterized in that: the ginseng plant stem cell factor is ginsenoside, and the ginseng plant stem cell factor obtained by extracting, purifying and drying ginseng has the biological activities of resisting bacteria, viruses and tumors.
3. A bacteriostatic composition according to claim 1, comprising plant stem cell factor, characterized in that: the antibacterial agent can be selected from berberine, dencichine, lonicera extract, pachymaran, radix rehmanniae Preparata glycoside, cortex Mori extract, and Echinacea glycoside,
the berberine is a main component extracted from rhizoma Coptidis;
the dencichine is a main component extracted from pseudo-ginseng:
the honeysuckle extract is a main component extracted from honeysuckle;
the pachyman is the main component extracted from Poria cocos;
the prepared rehmannia root glycoside is a main component extracted from prepared rehmannia root;
the cortex Mori extract is prepared from cortex Mori:
the Echinacoside is the main component extracted from Echinacoside,
the berberine, the sanchinin, the honeysuckle extract, the pachyman, the prepared rehmannia root glycoside, the sanguisorba officinalis extract and the echinacoside have broad-spectrum antibacterial, antiviral and antitumor biological activities, and the berberine and the honeysuckle extract also have good inhibition effects on intestinal pathogens and respiratory pathogens.
4. A bacteriostatic composition according to claim 1, comprising plant stem cell factor, characterized in that: the natural humectant is one or more of hyaluronic acid, glycerol, natural plant essence, squalane, etc., and the bioactive substances are one or more of vitamin E, collagen, mel, etc.
5. A bacteriostatic composition according to claim 1, comprising plant stem cell factor, characterized in that: the auxiliary material may be selected to constitute one or more of a buffer and an auxiliary agent,
the components of the buffer are radix scutellariae extract, radix sophorae flavescentis extract and radix paeoniae alba extract, and the buffer has the effects of clearing heat and detoxicating, diminishing inflammation and easing pain, resisting bacteria and resisting viruses and can effectively relieve symptoms such as gastrointestinal inflammation and ulcer;
the auxiliary agent comprises a polymer and a solvent.
6. A bacteriostatic composition according to claim 1, comprising plant stem cell factor, characterized in that: the plant extract/derivative comprises extracts/derivatives of one or more plants selected from dwarf lilyturf tuber, liquorice, platycodon root, mulberry leaf, chrysanthemum, dark plum fruit and double flowers, and the positive charge of the plant extract/derivative is realized by the following steps: the plant extracts/derivatives are subjected to a plasma chemical reaction in a plasma reactor and then spread on a negatively charged wafer substrate to attract positive charges to chelate with the plant extracts/derivatives and to wick away negative charges through the positively charged wafer substrate disposed in the opposite direction.
7. A process for preparing a bacteriostatic composition comprising a plant stem cell factor according to claims 1-6, characterized in that:
s1: firstly, ginseng is taken, water is added, distillation and extraction are carried out under the conditions of the temperature of 65 ℃ to 75 ℃ and the vacuum degree of 0.06Mpa to 0.07Mpa, when the volume of distillate is half of the water adding amount, distillation is stopped, and collection is carried out, and at the moment, a first distillate can be obtained;
s2: continuously adding water into the rest feed liquid, then distilling and extracting at 70-80 ℃ and 0.05-0.06 Mpa, stopping distillation when the volume of the distillate is half of the water adding amount, and collecting, wherein a second distillate can be obtained;
s3: mixing the first distillate and the second distillate obtained in the step S1, and obtaining an extract containing the ginseng plant stem cell factor;
s4: the extract containing the ginseng plant stem cell factor is purified by adopting an ethanol fractional precipitation method, and the precipitation amounts are respectively 1.68%, 1.37%, 3.47%, 41.70%, 15.26%, 7.25%, 4.71% and 3.13%, the precipitation I is detected to the precipitation 8 by HPLC, and the detection result shows that the proportion of the main peak of the precipitation component is gradually increased along with the increase of the ethanol addition amount, and the proportion of the main peak of the precipitation component is increased from 72.3% of the precipitation 1 to 96.6% of the precipitation 8. The purity of the sediment 5 to the sediment 8 is above 96 percent, and the molecular mass is about 1800D, which can be regarded as the same substance, and then the substances are combined, and the purified substance containing the ginseng plant stem cell factor can be obtained at the moment;
s5: mixing the purified ginseng plant stem cell factor-containing material with one or more antimicrobial agents, and then obtaining a primary ginseng plant stem cell factor-containing mixture;
s6: preparing extracts/derivatives of one or more plants selected from radix Ophiopogonis, glycyrrhrizae radix, radix Platycodi, folium Mori, flos Chrysanthemi, mume fructus and flos Lonicerae, treating the extracts/derivatives in a plasma reactor for 0-24 hr for plasma chemical reaction, spreading on negatively charged wafer substrate to attract positive charges to chelate with the extracts/derivatives, sucking negative charges away via positively charged wafer substrate arranged in opposite direction to obtain positively charged extracts/derivatives, and mixing the positively charged extracts/derivatives with primary mixture containing Ginseng plant stem cell factor to obtain secondary mixture containing Ginseng plant stem cell factor;
s7: mixing the secondary mixture containing the ginseng plant stem cell factor with one or more natural moisturizers and bioactive substances, and then obtaining a tertiary mixture containing the ginseng plant stem cell factor;
s8: adding one or more auxiliary materials into the tertiary mixture containing the ginseng plant stem cell factor, and mixing to prepare the antibacterial composition containing the ginseng plant stem cell factor.
8. The method for preparing a bacteriostatic composition containing plant stem cell factors according to claim 6, which is characterized in that: the preparation method of the antibacterial composition comprises the steps of S5, S6 and S8: the total mass percentage of the antibacterial agent is 0.1 to 10 percent; the concentration of the positively charged plant extract/derivative ranges from 0.0001mg/ml to 100mg/ml, and the total mass percentage of the auxiliary material is 90% to 99.9%.
9. The method for preparing a bacteriostatic composition containing plant stem cell factors according to claim 6, which is characterized in that: the ratio of the antibacterial agent, the natural humectant and the bioactive substances mixed in the steps S5 and S7 of the preparation method of the antibacterial composition is 3:1:1.
10. The method for preparing a bacteriostatic composition containing plant stem cell factors according to claim 7, which is characterized in that: the antibacterial composition containing the plant stem cell factor in the step S8 of the preparation method of the antibacterial composition can be prepared into oral medicines of 0.1 to 10 g, external medicines of 0.5 to 5 g and injections of 0.05 to 1 g.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310535092.2A CN116549612A (en) | 2023-05-12 | 2023-05-12 | Antibacterial composition containing plant stem cell factor and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310535092.2A CN116549612A (en) | 2023-05-12 | 2023-05-12 | Antibacterial composition containing plant stem cell factor and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116549612A true CN116549612A (en) | 2023-08-08 |
Family
ID=87485689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310535092.2A Pending CN116549612A (en) | 2023-05-12 | 2023-05-12 | Antibacterial composition containing plant stem cell factor and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116549612A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117100679A (en) * | 2023-10-07 | 2023-11-24 | 佰东靶向(深圳)生物科技有限公司 | Plant stem cell factor and preparation method and application thereof |
-
2023
- 2023-05-12 CN CN202310535092.2A patent/CN116549612A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117100679A (en) * | 2023-10-07 | 2023-11-24 | 佰东靶向(深圳)生物科技有限公司 | Plant stem cell factor and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103110868B (en) | Skin care solution and preparation method thereof | |
CN108785200B (en) | Antibacterial, acne-removing and anti-wrinkle silver ion moisturizing mask liquid, mask and preparation method of mask | |
CN111744054B (en) | Antibacterial wound surface dressing capable of promoting healing and preparation method thereof | |
CN102813751B (en) | Wound treatment agent | |
CN116549612A (en) | Antibacterial composition containing plant stem cell factor and preparation method thereof | |
CN110693997A (en) | Preparation for removing putrefaction and promoting granulation of scald and burn and preparation method thereof | |
CN111202770A (en) | Antibacterial Chinese herbal medicine compound preparation, preparation method and hand sanitizer | |
CN108066224B (en) | Stomach-soothing and ulcer-relieving toothpaste and preparation method thereof | |
CN107913234B (en) | Pilose antler grass toothpaste and preparation method thereof | |
CN110960583A (en) | Pharmaceutical composition for treating acne and application thereof | |
CN115300436A (en) | Bletilla striata composition with antibacterial and skin care functions and preparation method thereof | |
CN103610841A (en) | Method for treating stomatitis of bamboo rats | |
CN106619286A (en) | Beauty traditional Chinese medicinal facial mask capable of preventing and treating acnes | |
CN1246001C (en) | 'Fufukang' Chinese traditional medicine preparation and preparing process thereof | |
CN103446564B (en) | Chinese medicine composition of a kind of anti-inflammation and preparation method thereof | |
CN112168931B (en) | A pharmaceutical composition for treating oral ulcer, and its preparation method | |
CN103599205B (en) | Traditional Chinese medicine liquid of control wound infection and preparation method thereof | |
CN112089802A (en) | Traditional Chinese medicine formula for treating tumor-stage immunodeficiency and preparation method | |
CN115414295B (en) | Compound plant acne-removing mite-inhibiting composition and preparation method and application thereof | |
CN102940776B (en) | Compound nervilia fordii granule and preparation method thereof and application in preventing porcine respiratory diseases | |
CN1094291A (en) | Houttuynia oral administration liquid | |
CN110251564B (en) | External medicine for treating gouty arthritis and preparation method thereof | |
CN107397858B (en) | One kind treats dermopathic externally applied drug and preparation method | |
CN1352971A (en) | Eczema tablet | |
CN105560633B (en) | Double-elimination three-way aphtha stopping powder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |